Company Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.

The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

The company is headquartered in Cambridge, Massachusetts.

Enveric Biosciences, Inc.

Country	United States
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Joseph Tucker

Contact Details

Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States
Website	enveric.com

Stock Details

Ticker Symbol	ENVB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0000890821
CUSIP Number	29405E208
ISIN Number	US29405E4061
Employer ID	95-4484725
SIC Code	2834

Key Executives

Name	Position
Dr. Joseph Edward Tucker Ph.D.	Chief Executive Officer and Director
Kevin M. Coveney CPA	Chief Financial Officer
Dr. Peter J. Facchini Ph.D.	Chief Innovation Officer

Latest SEC Filings

Date	Type	Title
Oct 27, 2025	DEF 14A	Other definitive proxy statements
Oct 23, 2025	8-K	Current Report
Oct 10, 2025	PRE 14A	Other preliminary proxy statements
Oct 3, 2025	SCHEDULE 13G	Filing
Oct 3, 2025	D	Notice of Exempt Offering of Securities
Sep 29, 2025	S-3	Registration statement under Securities Act of 1933
Sep 24, 2025	SCHEDULE 13G	Filing
Sep 18, 2025	8-K	Current Report
Sep 2, 2025	8-K	Current Report
Aug 29, 2025	8-K	Current Report

View All SEC Filings